Other substances

Rilapladib

A lipoprotein-associated phospholipase A2 inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Rilapladib is an investigational drug for treatment of atherosclerosis and cardiovascular disorders (DrugBank).


Rilapladib on PubChem

 

Structure image - Rilapladib

COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C5=CC=CC=C5C(=O)C=C4SCC6=C(C(=CC=C6)F)F

Supporting references

Link Tested on Impact factor Notes Publication date
Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis
in silico 4.24

Predicted to interrupt SARS-CoV-2 Spike-RBD-ACE2 complex and thereby block viral entry.

 Jul/23/2020
Export (.csv)